Richard Vaillant has been appointed senior vice president and chief financial officer of Cytovance Biologics. Mr. Vaillant has more than 26 years of financial operations and management experience in the life sciences industry. Previously, he served as chief financial officer, treasurer and secretary of Histogenics Corp., where he was responsible for all financial operations, information systems and human resources.

Ulrich Ernst has been appointed vice president of operations. Mr. Ernst is a biotechnology industry leader with more than 20 years of domestic and global experience. Prior to joining the company, Mr. Ernst served as vice president of manufacturing at Alexion, where he led the efforts to gain FDA and EMA site approvals for Soliris.

Valerie McDonnell has been appointed vice president of sales and business development. Ms. McDonnell is responsible for oversight of all sales and marketing functions. Ms. McDonnell has more than 22 years of experience in the biotech industry. Prior to joining the company, she served as vice president of sales at Althea, where she had overall responsibility for all client relationship development.

“We are fortunate to have these professionals join our Cytovance team. They bring a combination of strong biologics business experience, proven results and goal-oriented leadership,” said Darren Head, president and chief executive officer of Cytovance Biologics. “We look forward to benefiting from their experiences across a variety of roles and businesses throughout the world.”